This study highlighted the occurrence of TP53 de novo mutations in medulloblastoma patients, pointing out that germline testing should be offered to patients with SHH-type medulloblastoma and p53 overexpression, regardless of family history. The gene discussed is TP53; the disease is medulloblastoma.